ライフサイエンスコーパス: nephrolithiasis

1 ith PHPT, of whom 265 (8%) were symptomatic (nephrolithiasis).

2 ote the development of treatment strategy in nephrolithiasis.

3 Sixty-one percent had nephrolithiasis.

4 alate increases the risk for calcium oxalate nephrolithiasis.

5 on, which could potentiate the risk of renal nephrolithiasis.

6 e dietary oxalate as a major risk factor for nephrolithiasis.

7 e 2 diabetes at increased risk for uric acid nephrolithiasis.

8 cal prevention, and surgical intervention of nephrolithiasis.

9 contribute to the hypercalciuria and calcium nephrolithiasis.

10 conducted of 45,619 men without a history of nephrolithiasis.

11 ke seems to increase the risk of symptomatic nephrolithiasis.

12 ally invasive techniques in the treatment of nephrolithiasis.

13 is inappropriate in patients with recurrent nephrolithiasis.

14 eceptor (VDR) in target tissues; and calcium nephrolithiasis.

15 itical for understanding the pathogenesis of nephrolithiasis.

16 id peroxidation during hyperoxaluria-induced nephrolithiasis.

17 hyperoxaluria and idiopathic calcium oxalate nephrolithiasis.

18 ic metabolic acidosis, nephrocalcinosis, and nephrolithiasis.

19 ces, paraesthesias, hyperbilirubinaemia, and nephrolithiasis.

20 n and improved accuracy in the evaluation of nephrolithiasis.

21 c roles of rs1256328 and rs12654812 in human nephrolithiasis.

22 with HIV infection, has been associated with nephrolithiasis.

23 provide a suitable model of human hereditary nephrolithiasis.

24 fficiency, or hypercalciuria with or without nephrolithiasis.

25 disease phenotypes such as hypercalcemia and nephrolithiasis.

26 ciated with higher risk of hyperoxaluria and nephrolithiasis.

27 nockout (PKO) mice exhibit hyperoxaluria and nephrolithiasis.

28 pted oxalate homeostasis and calcium oxalate nephrolithiasis.

29 evel, headache, urinary tract infection, and nephrolithiasis.

30 xa were less abundant among individuals with nephrolithiasis.

31 r patients who may be at risk for developing nephrolithiasis.

32 orphisms associated with the pathogenesis of nephrolithiasis.

33 al insights to stop the growing incidence of nephrolithiasis.

34 re previously reported to be associated with nephrolithiasis.

35 cidence of hyperoxaluria and calcium oxalate nephrolithiasis.

36 ted sequelae, including nephrocalcinosis and nephrolithiasis.

37 ons as causing a recessive Mendelian form of nephrolithiasis.

38 TRPV5 channel activity and protects against nephrolithiasis.

39 Hypercalciuria is a major risk factor for nephrolithiasis.

40 ecision medicine approaches in patients with nephrolithiasis.

41 se stone recurrence in patients with calcium nephrolithiasis.

42 es have been associated with a lower risk of nephrolithiasis.

43 st 2 L of urine per day to prevent recurrent nephrolithiasis.

44 rt an adverse effect of high temperatures on nephrolithiasis.

45 biota and short chain fatty acids (SCFAs) in nephrolithiasis.

46 ed claudin-14 associated with hypercalciuric nephrolithiasis.

47 risk of radiation exposure to patients with nephrolithiasis.

48 scribes a 60-year-old patient with bilateral nephrolithiasis.

49 roxaluria or even idiopathic calcium oxalate nephrolithiasis.

50 promising adjuncts for preventing recurrent nephrolithiasis.

51 lly considered a poor experimental model for nephrolithiasis.

52 variant(s) are candidate risk modifiers for nephrolithiasis.

53 cystic kidney disease (3.03, 1.26-7.31), and nephrolithiasis (1.89, 1.96-2.97).

54 stinuria is the commonest inherited cause of nephrolithiasis (~1% in adults; ~6% in children) and is

55 patients, 50 (35.7%) had CKD, 46 (32.9%) had nephrolithiasis, 18 (12.9 %) had nephritis, and 50 (35.7

56 red with the high-dose scan were as follows: nephrolithiasis, 91%; ureterolithiasis, 94%; obstruction

57 Nephrolithiasis, a condition in which urinary supersatur

58 ntribute to the recent increase in pediatric nephrolithiasis, a definite underlying cause remains elu

59 nts with primary or secondary hyperoxaluria, nephrolithiasis, acute or chronic oxalate nephropathy, o

60 ue from normal rats and rats developing CaOx nephrolithiasis after challenge with ethylene glycol.

61 n mRNA expression in rat kidneys during CaOx nephrolithiasis after challenge with ethylene glycol.

62 luoroscopy used during surgical treatment of nephrolithiasis also contributes to patient radiation ex

63 yndrome have resulted in increasing rates of nephrolithiasis among women, decreasing the male-to-fema

64 the absence of a diagnosis of gout or urate nephrolithiasis, an emerging body of evidence supports a

65 studies estimate a heritability of >45% for nephrolithiasis and >50% for hypercalciuria.

66 association analysis using 624 patients with nephrolithiasis and 1008 control subjects.

67 ations describing the link between pediatric nephrolithiasis and bone metabolism.

68 ociations also persisted among patients with nephrolithiasis and concomitant gout, with a rate ratio

69 X-linked nephrolithiasis and engineered deficiencies in some othe

70 Patients with recurrent calcium nephrolithiasis and fasting hypercalciuria have a higher

71 Patients with recurrent calcium nephrolithiasis and idiopathic fasting hypercalciuria (u

72 nderstand that a relationship exists between nephrolithiasis and low BMD.

73 important factors in the pathophysiology of nephrolithiasis and low bone density.

74 The increased oxalate excretion can cause nephrolithiasis and nephrocalci-nosis and can, in some c

75 est that knowledge of the molecular cause of nephrolithiasis and nephrocalcinosis may have practical

76 ccumulation of oxalate in humans may lead to nephrolithiasis and nephrocalcinosis.

77 thrive in children, osteomalacia in adults, nephrolithiasis and nephrocalcinosis.

78 may account for the lower incidence of both nephrolithiasis and osteoporosis in black women.

79 nced CT (5-mm section width, no overlap) for nephrolithiasis and other causes of twinkling artifact.

80 between the induction of hyperoxaluria/CaOx nephrolithiasis and the expression of the bikunin gene i

81 Of these, 7 (3%) had nephrolithiasis and the other 12 (5%) had previously und

82 Nephrolithiasis and/or urolithiasis presence was indepen

83 oups, with 3 cases of hypercalcemia, none of nephrolithiasis, and 249 falls observed.

84 ) tubulointerstitial nephritis, and 1 (3.3%) nephrolithiasis, and 3 (10%) had an unknown cause of kid

85 ydrate, the most common solid phase in human nephrolithiasis, and also inhibits the nucleation, growt

86 ), reducing the risk of subsequent fracture, nephrolithiasis, and chronic kidney disease (CKD), but i

87 n guide therapy to prevent nephrocalcinosis, nephrolithiasis, and potentially, CKD.

88 olecular-weight proteinuria, hypercalciuria, nephrolithiasis, and renal failure.

89 t may increase the risk of nephrocalcinosis, nephrolithiasis, and renal insufficiency.

90 cribing further uses of alpha-antagonists in nephrolithiasis, and reporting improvements in extracorp

91 have been described as being associated with nephrolithiasis, and these mutations explain about 15% o

92 ly presents with nephrocalcinosis, recurrent nephrolithiasis, and/or early chronic kidney disease, th

93 l: 0.66, 0.90) positive predictive value for nephrolithiasis anywhere in the kidneys at CT.

94 RECENT FINDINGS: Patients with nephrolithiasis are at risk for significant radiation ex

95 e of bacteria in the pathogenesis of calcium nephrolithiasis are discussed.

96 dney stones (also known as urinary stones or nephrolithiasis) are highly prevalent, affecting approxi

97 nd was detectable for long-bone fracture and nephrolithiasis as well as among children.

98 dney stone cases, suggesting that additional nephrolithiasis-associated genes remain to be discovered

99 cases and 417,378 controls, and identify 20 nephrolithiasis-associated loci, seven of which are prev

100 o establish the relationship between calcium nephrolithiasis, bone densitometry scoring, and bone min

101 's disease, also known as X-linked recessive nephrolithiasis, but the effects of diuretics on calcium

102 h ambient temperatures are a risk factor for nephrolithiasis, but the precise relationship between te

103 Obesity is a strong risk factor for nephrolithiasis, but the role of physical activity and c

104 ncrease of 1.6-2.2 million lifetime cases of nephrolithiasis by 2050, representing up to a 30% increa

105 inhibitors (SGLT2is) might lower the risk of nephrolithiasis by altering urine composition.

106 rted that Uromodulin (UMOD) protects against nephrolithiasis by upregulating the renal calcium channe

107 t in the denosumab to teriparatide group had nephrolithiasis, classified as being possibly related to

108 s with T2D, SGLT2i use may lower the risk of nephrolithiasis compared with GLP-1RAs or DPP4is and cou

109 Three disorders of hypercalciuric nephrolithiasis (Dent's disease, X-linked recessive neph

110 Advances in the management of nephrolithiasis depend on combined efforts of clinicians

111 ques and the renal papillae in patients with nephrolithiasis, detailing genetic discoveries related t

112 The primary outcome was nephrolithiasis diagnosed by International Classificatio

113 stone formation, excessive uptake results in nephrolithiasis due to hypocitraturia.

114 serum calcium concentration and a number of nephrolithiasis episodes while the DGKD-associated locus

115 100% more than control conditions) and fewer nephrolithiasis events (15 fewer events per 100 particip

116 The primary outcome was recurrent nephrolithiasis events ascertained from diagnoses during

117 ility of treatment weighting, 1924 recurrent nephrolithiasis events occurred among the 14 456 weighte

118 Protective associations persisted for nephrolithiasis events that required emergency departmen

119 Nephrolithiasis exhibits marked pathophysiological heter

120 ant advances have been made in understanding nephrolithiasis from single gene defects, the understand

121 tudies have identified slc26a6 as an oxalate nephrolithiasis gene in the mouse.

122 ient population is all adults with recurrent nephrolithiasis (>/=1 prior kidney stone episode).

123 (n=12), patients (n=12) with hypercalciuric nephrolithiasis had significantly decreased levels of ur

124 However, for the majority of individuals, nephrolithiasis has a multifactorial aetiology involving

125 The incidence of pediatric nephrolithiasis has been steadily increasing for the pas

126 The prevalence of nephrolithiasis has increased substantially over the pas

127 Recent studies in nephrolithiasis have investigated why stones form, impro

128 in adults, the trends occurring in pediatric nephrolithiasis have not been studied rigorously, which

129 ying both monogenic and polygenic factors in nephrolithiasis, have revealed that the following have i

130 idiopathic, secondary and Mendelian forms of nephrolithiasis, identify systemic disease associations

131 Readers 1, 2, and 3 detected nephrolithiasis in 129, 127, and 129 patients and 94, 94

132 studies to investigate the correlations with nephrolithiasis in a Taiwanese population.

133 ry and pharmacologic management of recurrent nephrolithiasis in adults.

134 Type 2 diabetes is a risk factor for nephrolithiasis in general and has been associated with

135 LC34A1 gene can lead to hypophosphatemia and nephrolithiasis in humans remains unknown.

136 citrate, or allopurinol to prevent recurrent nephrolithiasis in patients with active disease in which

137 The main risk factor for uric acid nephrolithiasis in patients with type 2 diabetes is a lo

138 relation between oxalate intake and incident nephrolithiasis in the Health Professionals Follow-up St

139 ated with SGLT-2 inhibitor for patients with nephrolithiasis in these target trial emulations suggest

140 Nephrolithiasis incidence is increasing in children and

141 regard to operative guidelines, a history of nephrolithiasis increased the odds of parathyroidectomy

142 , hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced

143 the lithotripsy technology for treatment of nephrolithiasis, intravascular lithotripsy is a new tech

144 Recurrent nephrolithiasis is a burden to the individual patient as

145 Nephrolithiasis is a common disease affecting almost all

146 Nephrolithiasis is a not infrequent complication of preg

147 These findings may partly explain why nephrolithiasis is a predominantly male disease.

148 Nephrolithiasis is a prevalent condition with a high mor

149 Nephrolithiasis is a worldwide problem with increasing p

150 linicians look for the underlying causes for nephrolithiasis is imperative to direct management.

151 h may indicate astronauts' increased risk of nephrolithiasis is in part a primary renal phenomenon ra

152 e disease, the best management for recurrent nephrolithiasis is likely a combination of surgical and

153 Furthermore, nephrolithiasis is now recognized as a systemic conditio

154 Nephrolithiasis is often associated with increased super

155 Nephrolithiasis is one of the most common conditions aff

156 Calcium nephrolithiasis is the most common form of renal stone d

157 Nephrolithiasis is the most common health condition affe

158 Kidney stone disease (nephrolithiasis) is a common problem that can be associa

159 Kidney stone disease (nephrolithiasis) is a major clinical and economic health

160 rtrophy, complicated by nephrocalcinosis and nephrolithiasis, is reported here.

161 Nephrolithiasis (kidney stones) affects 5-10% of adults

162 Xp11.22, are associated with hypercalciuric nephrolithiasis (kidney stones) in the Northern European

163 terized by hypercalciuria, nephrocalcinosis, nephrolithiasis, low molecular weight proteinuria, Fanco

164 ldren and 166 adults) from 268 families with nephrolithiasis (n=256) or isolated nephrocalcinosis (n=

165 isease such as chronic kidney disease (CKD), nephrolithiasis, nephritis, and renal failure syndrome w

166 s leading to multisystem oxalate deposition, nephrolithiasis, nephrocalcinosis and end-stage renal di

167 s a cornerstone in the care of patients with nephrolithiasis, obesity, hypertension, and chronic kidn

168 Nephrolithiasis occurred in 12 of 33 patients (36%).

169 kidney (ALPL)) have higher susceptibility to nephrolithiasis (odds ratio (OR) = 2.03, p = 0.0013).

170 catabolite uric acid in the kidneys, causing nephrolithiasis or crystalluria, and the joints, causing

171 chronic kidney disease and nephrocalcinosis/nephrolithiasis or with end stage kidney disease of unce

172 ng 14 (RGS14)) have higher susceptibility to nephrolithiasis (OR = 1.91, p = 0.0017).

173 on diagnosis codes indicating osteoporosis, nephrolithiasis, or stage 3 CKD.

174 a (P = 0.02) were associated with PTx; while nephrolithiasis (P = 0.07) and osteoporosis (P = 0.34) d

175 In total, 454 nephrolithiasis patients were recruited from Kaohsiung M

176 ninvasive first-line therapy for millions of nephrolithiasis patients, has not improved substantially

177 Among nephrolithiasis patients, subjects with GG at rs7627468

178 In a validation cohort of only nephrolithiasis patients, the CYP24A1-associated locus c

179 parathyroid hyperplasia with a high rate of nephrolithiasis, persistent and recurrent HPT.

180 d and Drug Industry is paramount to reducing nephrolithiasis rates and its complications.

181 are of the amount of radiation patients with nephrolithiasis receive.

182 current treatments to simultaneously manage nephrolithiasis recurrence and comorbidities, including

183 lly explain the high human susceptibility to nephrolithiasis relative to that of mouse.

184 s considerable clinical and societal burden, nephrolithiasis remains under-recognized, underserved an

185 Secondary outcomes included nephrolithiasis resulting in hospital admission or emerg

186 velopment was evaluated after adjustment for nephrolithiasis risk factors.

187 gated the association between SGLT2i use and nephrolithiasis risk in patients receiving routine care

188 The association between SGLT2i use and nephrolithiasis risk was similar by sex, race and ethnic

189 that they play distinct roles in IBD-induced nephrolithiasis risk.

190 nd colonic involvement consistent with known nephrolithiasis risk.

191 l imaging method for patients with suspected nephrolithiasis should be computed tomography (CT) or ul

192 Patients symptomatic with nephrolithiasis, significant osteoporosis, bone pain, an

193 expressed in Xenopus oocytes and in reported nephrolithiasis susceptibility.

194 n have a higher incidence of calcium oxalate nephrolithiasis than women.

195 nce is raised by factors unique to pediatric nephrolithiasis that could expose an affected child to m

196 a change in the current trends of pediatric nephrolithiasis that is characterized by a significant i

197 Among those with recently active nephrolithiasis, the absolute rate difference was 219 pe

198 opportunities to learn more about pediatric nephrolithiasis, thereby fueling the much-needed researc

199 inkling artifact is commonly associated with nephrolithiasis, this finding is relatively insensitive

200 d to the emergency department with suspected nephrolithiasis to undergo initial diagnostic ultrasonog

201 betes, prior topiramate treatment, recurrent nephrolithiasis, type 1 diabetes, use of insulin within

202 risks of depression, cardiovascular disease, nephrolithiasis, type 2 diabetes mellitus, and higher ur

203 ing dysfunction, flank pain, abdominal pain, nephrolithiasis, urinary tract infection and decreased b

204 is review describes the relationship between nephrolithiasis, vascular disease and metabolic syndrome

205 ow-up of 192 (IQR, 88-409) days, the risk of nephrolithiasis was lower in patients initiating an SGLT

206 Nephrolithiasis was predictive of PTx (OR 2.94 vs asympt

207 ditional genes whose mutations are linked to nephrolithiasis, we performed targeted next-generation s

208 te the focal nature of mineral deposition in nephrolithiasis, we uncover a global injury signature ch

209 ups; no cases of hypercalcemia and 1 case of nephrolithiasis were reported in the placebo group.

210 Kidney stones (nephrolithiasis), which affect 12% of males and 5% of fe

211 benefits of water intake on weight loss and nephrolithiasis, while single studies raised the possibi

212 scribed for patients with idiopathic calcium nephrolithiasis, who account for > 80% of new diagnoses

213 .S. population living in high-risk zones for nephrolithiasis will grow from 40% in 2000 to 56% by 205

214 sed our understanding of the pathogenesis of nephrolithiasis, will hopefully facilitate the future de

215 e cost increase associated with this rise in nephrolithiasis would be $0.9-1.3 billion annually (year

216 ithiasis (Dent's disease, X-linked recessive nephrolithiasis (XRN), and X-linked recessive hypophosph